The White House declined to comment on Pfizer's deal, but a spokesman told reporters in a briefing that Congress should take action to prevent more such transactions.
The U.S. Treasury Department last week unveiled new rules to clamp down on inversions, its second attempt to do so since a wave of deals peaked in September 2014. But the latest rules amounted to tweaks of existing law and will not impede the Pfizer-Allergan transaction, tax experts said.
14:56 Read what Steven Mnuchin will say at his Treasury confirmation hearing17
05:10 Hard-Luck Hillary Clinton’s Second Case of the Inaugural Blues2
23:46 ‘American Crime Story’ to take on Monica Lewinsky scandal: report
16:31 What will Jared Kushner and Donald Trump's Middle East look like?14